Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Here’s Why

Astellas Pharma Inc. (OTCMKTS:ALPMY) gapped up prior to trading on Monday . The stock had previously closed at $13.21, but opened at $13.7999. Astellas Pharma shares last traded at $13.28, with a volume of 845 shares changing hands.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ALPMY shares. Zacks Research raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. Two equities research analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Astellas Pharma Stock Performance

The company has a current ratio of 1.17, a quick ratio of 0.90 and a debt-to-equity ratio of 0.17. The firm has a fifty day moving average price of $13.64 and a 200 day moving average price of $14.64. The firm has a market cap of $24.02 billion, a PE ratio of 12.36 and a beta of 0.07.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings results on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 23.54%. The firm had revenue of $3.38 billion for the quarter, compared to analysts’ expectations of $3.28 billion. As a group, equities research analysts expect that Astellas Pharma Inc. will post 1.25 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).